Skip to content
  • Wednesday, 28 October 2026
  • 12:31 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • FDA Approves Pfizer’s Tukysa Regimen as Frontline Maintenance Therapy for Advanced HER2-Positive Breast Cancer
Pharmaceutical R&D

FDA Approves Pfizer’s Tukysa Regimen as Frontline Maintenance Therapy for Advanced HER2-Positive Breast Cancer

Teuku Ryan Oct 12, 2026 0

The United States Food and Drug Administration (FDA) has granted regulatory approval to Pfizer’s targeted oncology medication Tukysa (tucatinib) in…

Read More
Pharmaceutical R&D

Biohaven and Ono Pharmaceutical Forge Up to $100m Licensing Deal for Advanced IgG Degrader Portfolio in Asia

Teuku Ryan Oct 11, 2026 0

The global biopharmaceutical landscape witnessed a significant strategic alliance as Biohaven Ltd. announced a landmark licensing and regional partnership agreement…

Read More
Pharmaceutical R&D

Bio-Techne Corporation Expands Global Cell Therapy Capabilities With New GMP Small Molecule Manufacturing Facility in Bristol

Teuku Ryan Oct 10, 2026 0

Life science tools and diagnostics provider Bio-Techne Corporation has officially opened a state-of-the-art, purpose-built manufacturing facility in Bristol, United Kingdom,…

Read More
Pharmaceutical R&D

Roche Secures FDA Approval for Tecentriq in Stage III dMMR Colon Cancer Setting to Establish New Treatment Paradigm

Teuku Ryan Oct 10, 2026 0

The pharmaceutical landscape for gastrointestinal oncology has undergone a significant transformation following a landmark regulatory decision by the US Food…

Read More
Pharmaceutical R&D

AI-Driven Oncology Pioneer Iambic Therapeutics Targets $135m Nasdaq IPO in Banner Year for Biotech Listings

Teuku Ryan Oct 9, 2026 0

Iambic Therapeutics, an oncology-focused biotechnology company recognized for its pioneering intersection of artificial intelligence and drug discovery, has officially set…

Read More
Pharmaceutical R&D

Viatris Expands Into Non-Opioid Pain Market With $1.65bn Acquisition of Pacira BioSciences

Teuku Ryan Oct 9, 2026 0

The global pharmaceutical landscape is undergoing a profound structural shift as healthcare enterprises aggressively pivot away from traditional opioid-based narcotics…

Read More
Pharmaceutical R&D

WHO Issues Landmark Global Guidelines Urging Lifestyle Interventions Over Weight Loss Drugs for Pediatric Obesity

Teuku Ryan Oct 8, 2026 0

The World Health Organization (WHO) has released its first-ever comprehensive global guidelines addressing child and adolescent obesity, establishing a clear…

Read More
Pharmaceutical R&D

Suspected Plague Outbreak in Russia Public Health Risk Lower Than Covid-19

Teuku Ryan Oct 8, 2026 0

Global health authorities and epidemiological experts have closely monitored developments surrounding a suspected plague outbreak in Russia, with initial risk…

Read More
Pharmaceutical R&D

KymaThera pulls in $80m to bring breast cancer drug to clinic  – Pharmaceutical Technology

Teuku Ryan Oct 7, 2026 0

San Diego-based biopharmaceutical company KymaThera has successfully closed an $80 million Series B financing round to propel its lead oncology…

Read More
Pharmaceutical R&D

Roche Acquires Global Rights to Alector’s Parkinson’s Disease Candidate AL050 in Landmark $1.27bn Deal

Teuku Ryan Oct 7, 2026 0

Swiss pharmaceutical giant Roche has secured global rights to Alector’s prominent preclinical Parkinson’s disease candidate, AL050, in a lucrative transaction…

Read More

Posts pagination

1 2 3 4 … 43
TWiV 1289: Building a better hepatitis B trapBridging Algorithmic Design and Regulatory Standards in Enterprise AIA little birdie told us that immune genes influence the gut microbiome and vice versaEngineered Immune Receptors Offer New Hope Against Global Crop-Destroying Fungal Pathogens
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactEliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic ProportionsMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
The oral exposure challenge in PROTACs: What drug developers need to solve earlyThe Silence Broken: How Brain-Computer Interfaces are Restoring the Human Voice for Those Paralyzed by ALSESMO26: KEYNOTE-C93 Backs Chemo-Free Keytruda in dMMR Endometrial CancerThe Discovery of REM-like Sleep in Jumping Spiders Challenges Traditional Views of Animal Consciousness
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
The oral exposure challenge in PROTACs: What drug developers need to solve early
Lana Keisha Oct 28, 2026
Environmental & Analytical Chemistry
The Silence Broken: How Brain-Computer Interfaces are Restoring the Human Voice for Those Paralyzed by ALS
Abdurrohim Arsyad Oct 28, 2026
Pharmaceutical R&D
ESMO26: KEYNOTE-C93 Backs Chemo-Free Keytruda in dMMR Endometrial Cancer
Teuku Ryan Oct 28, 2026
Molecular & Cell Biology
The Discovery of REM-like Sleep in Jumping Spiders Challenges Traditional Views of Animal Consciousness
Angie Faith Oct 28, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ